### Cell Line Information Pack (CLIP)

Cell line name

UKBi011-A-1



#### **Purpose**

The purpose of this Cell Line Information Pack (CLIP) is to communicate cell line specific information to potential users of the cell line, and to confirm that a User has received it upon the purchase of an EBiSC cell line.

#### Information

The CLIP may provide a variety of types of information related to an individual cell line. Of particular importance are Third Party Obligations (TPOs), which are ethical or legal obligations of a Depositor related to the use of the cell line. TPOs may impose ethical or legal limitations on the ability of a User to use the cell line, or require steps to be taken before it can be used. TPOs are likely to be:

- Obligations under license to an intellectual property rights (patent) holder, or
- Restrictions on use imposed by the donor of the primary tissue from which the cell line was made.

Third Party Obligations: donor consent provisions

None.

## Third Party Obligations: IP or license provisions

iPS-AJ: This EBiSC Cell line was generated under the technology disclosed in patents related to iPS cells which are owned by Kyoto University and are licensable from iPS Academia Japan., Inc.("iPS AJ"). Commercial user (for-profit entity) acknowledges that, prior to receipt and use of this EBiSC Cell line, such commercial user needs to have an appropriate patent license from iPS AJ even for its research use. Academic user (academic or not-for-profit entity) acknowledges that such academic user does not need a patent license from iPS AJ for its research use, provided, however, that when such academic user uses this EBiSC Cell line for other than its independent research use, such academic user acknowledges that the academic user might need to obtain an appropriate patent license from iPS AJ. For inquiries to iPS AJ, please contact at license@ips-ac.co.jp.

CRISPR: The lines have been generated using CRISPR-Cas9 technology under a license with ERS Genomics. Commercial user (for-profit entity) acknowledges that, prior to receipt and use of such EBiSC Cell line, such commercial user needs to have an appropriate patent license from ERS Genomics even for its research use. For inquiries to ERS Genomics, please contact: <a href="legalnotices@ersgenomics.com">legalnotices@ersgenomics.com</a>.

#### Other information

Any publications or public dissemination of results using EBiSC iPSCs should be accompanied by the following acknowledgement: "The EBiSC Bank acknowledges Bioneer A/S as the source of the human induced pluripotent cell line UKBi011-A-1 which was generated with support from the EBiSC project. The EBiSC has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking (JU) under grant agreement  $n^{\circ}115582$  and from the IMI-2 JU under grant agreement No 821362, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013), European Union's Horizon 2020 research and innovation programme and EFPIA."



In case of queries, please get in touch via: Contact@EBiSC.org.

Doc Ref: XP-0040-4-1 V-7

CLIP Reference: UKBi011-A-1.CLIP.v3.pdf

Page 1 of 2

Cell line name

UKBi011-A-1



# SIGN AND RETURN THIS DOCUMENT WITH YOUR COMPLETED ACCESS AND USE AGREEMENT

## User acknowledgement

Name	Position
Signature	Date



In case of queries, please get in touch via: Contact@EBiSC.org.

Doc Ref: XP-0040-4-1 V-7

CLIP Reference: UKBi011-A-1.CLIP.v3.pdf

Page 2 of 2